Jaguar Health/$JAGX
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Jaguar Health
Jaguar Health Inc is a commercial-stage pharmaceutical company developing novel proprietary prescription medicines sustainably derived from plants from rainforest areas for gastrointestinal disease states in humans and animals. The Company focuses on conditions associated with overactive bowel, including chronic debilitating diarrhea, urgency, and bowel incontinence. It operates through two segments: animal health, which develops and commercializes products for animals, and human health, with the human health segment generating the maximum revenue and focusing on products such as Mytesi, focusing on human products, specifically Mytesi, approved for symptomatic relief of non-infectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
- Ticker
- $JAGX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 47
- Headquarters
- San Francisco, United States
- Website
- jaguar.health
Jaguar Health Metrics
BasicAdvanced
$251K
-
-$2,338.09
-0.06
-
Price and volume
Market cap
$251K
Beta
-0.06
52-week high
$1,039.50
52-week low
$0.36
Average daily volume
2.4M
Financial strength
Current ratio
0.739
Quick ratio
0.168
Long term debt to equity
0.395
Total debt to equity
2.533
Interest coverage (TTM)
-25.15%
Profitability
EBITDA (TTM)
-23.193
Gross margin (TTM)
82.31%
Net profit margin (TTM)
-130.85%
Operating margin (TTM)
-90.22%
Revenue per employee (TTM)
$590,000
Management effectiveness
Return on assets (TTM)
-38.04%
Return on equity (TTM)
-548.83%
Valuation
Price to revenue (TTM)
0
Price to book
0.02
Price to tangible book (TTM)
-0.02
Price to free cash flow (TTM)
-0.002
Free cash flow yield (TTM)
-62,500.00%
Free cash flow per share (TTM)
-300
Growth
Revenue change (TTM)
135.52%
3-year revenue growth (CAGR)
36.00%
Jaguar Health Financial Performance
Revenues and expenses
Jaguar Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Jaguar Health News
AllArticlesVideos
Jaguar Health's Crofelemer Shows Benefit for Intestinal Failure (IF) in Third Rare Congenital Enteropathy Disorder
Accesswire3 weeks ago
Jaguar Health Provides Update Regarding Special Stock Dividend
Accesswire4 weeks ago
Positive Preliminary Results Presented at Annual American College of Gastroenterology Meeting for Open-Label Study in Adult Short Bowel Syndrome Patients with Intestinal Failure (SBS-IF) with Jaguar Health's Crofelemer
Accesswire4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.